Historical Valuation
Eton Pharmaceuticals Inc (ETON) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.64 is considered Undervalued compared with the five-year average of 25.34. The fair price of Eton Pharmaceuticals Inc (ETON) is between 29.69 to 38.73 according to relative valuation methord. Compared to the current price of 15.68 USD , Eton Pharmaceuticals Inc is Undervalued By 47.19%.
Relative Value
Fair Zone
29.69-38.73
Current Price：15.68
47.19%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Eton Pharmaceuticals Inc (ETON) has a current Price-to-Book (P/B) ratio of 18.86. Compared to its 3-year average P/B ratio of 12.05 , the current P/B ratio is approximately 56.54% higher. Relative to its 5-year average P/B ratio of 10.06, the current P/B ratio is about 87.41% higher. Eton Pharmaceuticals Inc (ETON) has a Forward Free Cash Flow (FCF) yield of approximately 4.82%. Compared to its 3-year average FCF yield of 3.79%, the current FCF yield is approximately 27.22% lower. Relative to its 5-year average FCF yield of -0.49% , the current FCF yield is about -1091.28% lower.
P/B
Median3y
12.05
Median5y
10.06
FCF Yield
Median3y
3.79
Median5y
-0.49
Competitors Valuation Multiple
AI Analysis for ETON
The average P/S ratio for ETON competitors is 31.11, providing a benchmark for relative valuation. Eton Pharmaceuticals Inc Corp (ETON.O) exhibits a P/S ratio of 4.64, which is -85.08% above the industry average. Given its robust revenue growth of 117.54%, this premium appears sustainable.
Performance Decomposition
AI Analysis for ETON
1Y
3Y
5Y
Market capitalization of ETON increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ETON in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ETON currently overvalued or undervalued?
Eton Pharmaceuticals Inc (ETON) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.64 is considered Undervalued compared with the five-year average of 25.34. The fair price of Eton Pharmaceuticals Inc (ETON) is between 29.69 to 38.73 according to relative valuation methord. Compared to the current price of 15.68 USD , Eton Pharmaceuticals Inc is Undervalued By 47.19% .
What is Eton Pharmaceuticals Inc (ETON) fair value?
ETON's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Eton Pharmaceuticals Inc (ETON) is between 29.69 to 38.73 according to relative valuation methord.
How does ETON's valuation metrics compare to the industry average?
The average P/S ratio for ETON's competitors is 31.11, providing a benchmark for relative valuation. Eton Pharmaceuticals Inc Corp (ETON) exhibits a P/S ratio of 4.64, which is -85.08% above the industry average. Given its robust revenue growth of 117.54%, this premium appears sustainable.
What is the current P/B ratio for Eton Pharmaceuticals Inc (ETON) as of Jan 09 2026?
As of Jan 09 2026, Eton Pharmaceuticals Inc (ETON) has a P/B ratio of 18.86. This indicates that the market values ETON at 18.86 times its book value.
What is the current FCF Yield for Eton Pharmaceuticals Inc (ETON) as of Jan 09 2026?
As of Jan 09 2026, Eton Pharmaceuticals Inc (ETON) has a FCF Yield of 4.82%. This means that for every dollar of Eton Pharmaceuticals Inc’s market capitalization, the company generates 4.82 cents in free cash flow.
What is the current Forward P/E ratio for Eton Pharmaceuticals Inc (ETON) as of Jan 09 2026?
As of Jan 09 2026, Eton Pharmaceuticals Inc (ETON) has a Forward P/E ratio of 29.39. This means the market is willing to pay $29.39 for every dollar of Eton Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Eton Pharmaceuticals Inc (ETON) as of Jan 09 2026?
As of Jan 09 2026, Eton Pharmaceuticals Inc (ETON) has a Forward P/S ratio of 4.64. This means the market is valuing ETON at $4.64 for every dollar of expected revenue over the next 12 months.